AbbVie (NYSE: ABBV) is witnessing a strong momentum in premarket trading with a price change of $8.85, translating to a 5.0% increase, bringing the current premarket price to $184.5. This uptick comes after the company reported its fourth-quarter and full-year financial results for 2024, showcasing impressive growth across various sectors.
In the report released on January 31, 2025, AbbVie reported a full-year net revenue of $56.334 billion, reflecting a 3.7% increase on a reported basis and a 4.6% increase operationally. Notably, the immunology portfolio generated $26.682 billion in net revenues, a 2.1% increase, while the oncology portfolio achieved $6.555 billion, up 10.8% from the previous year. The global revenue from AbbVie’s neuroscience portfolio surged by 16.6%, indicating robust business growth and resilience.
CEO Robert A. Michael noted, "2024 was a year of significant progress for AbbVie. Our growth platform delivered outstanding results, we advanced our pipeline with key regulatory approvals, and we strengthened our business through strategic transactions." This strong performance has set a positive outlook for 2025, with anticipated adjusted diluted EPS guidance ranging from $12.12 to $12.32.
One of the highlights was the performance of AbbVie’s drugs Skyrizi and Rinvoq, which together are projected to exceed $31 billion in revenue by 2027, underscoring their critical role in AbbVie's growth strategy moving forward.
With a significant rise in premarket trading, investors are responding favorably to AbbVie’s financial results and strategic direction. This boost not only reflects confidence in the company's current products but also in its future growth trajectory as they continue to expand their portfolio with innovative treatments.
As market dynamics evolve, investors are keen to monitor ABBV’s performance in the upcoming quarters, especially with the promising guidance and robust revenue outlook highlighted in the latest financial disclosures.
